A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells

The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)

(2009) Jonathan A Winger et al.   BMC STRUCTURAL BIOLOGY

Eph-Ephrin Bidirectional Signaling in Physiology and Disease

(2008) Elena B. Pasquale   CELL

ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression

(2008) Dakshina M. Jandhyala et al.   CELLULAR MICROBIOLOGY

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

(2008) L L Remsing Rix et al.   LEUKEMIA

Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia

(2008) Claire Villalva et al.   LEUKEMIA & LYMPHOMA

Lipocalin 2 is required for BCR-ABL-induced tumorigenesis

(2008) X Leng et al.   ONCOGENE

Eph, a Protein Family Coming of Age: More Confusion, Insight, or Complexity?

(2008) M. Lackmann et al.   Science Signaling